Newsfiscal.ai
Mizuho Securities Maintains Neumora Therapeutics with Buy Rating, Adjusts Price Target
· Published
Article summary
Mizuho Securities analyst Graig Suvannavejh has maintained a 'Buy' rating on Neumora Therapeutics (NMRA) while lowering the price target from $4 to $3.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…